Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03681210 · ClinicalTrials.gov registry record

Destination Therapy Post Approval Study

A clinical trial of Chronic Heart Failure, sponsored by Medtronic Cardiac Rhythm and Heart Failure.

Active
Registry status
300
Enrollment target
20
Study locations

NCT03681210: Active study of Chronic Heart Failure, sponsored by Medtronic Cardiac Rhythm and Heart Failure.

NCT03681210 is a study of Chronic Heart Failure that is active but no longer recruiting, run by Medtronic Cardiac Rhythm and Heart Failure. The registered enrollment target is 300 participants, below the 397-participant average among 12 other Chronic Heart Failure trials with a reported enrollment target (24% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03681210, a study of Chronic Heart Failure, is active but no longer recruiting, sponsored by Medtronic Cardiac Rhythm and Heart Failure.

ACTIVE NOT RECRUITING
Registry status
300 participants
Enrollment target
20
Study locations

Study Summary

Medtronic is sponsoring the HeartWare™ HVAD™ Destination Therapy (DT) Post Approval Study (PAS) to further confirm safety and effectiveness of the HeartWare Ventricular Assist Device System (HVAD System) when used as intended, in "real-world" clinical practice. The Destination Therapy Post Approval Study (DT PAS) is conducted within Medtronic's Product Surveillance Platform.

Primary Outcome

Complications include death, disabling stroke, or device malfunction or failure requiring exchange, explantation or urgent transplantation.

Conditions Studied

Interventions

  • DEVICE HeartWare Ventricular Assist Device

Study Locations (20)

Florida

  • University of Miami - Coral Gables
  • Mayo Clinic (Jacksonville FL) - Jacksonville
  • AdventHealth - Orlando
  • University of South Florida Health - Tampa

California

  • University of California San Diego - San Diego
  • University of California San Francisco Medical Center - San Francisco
  • Stanford University Hospital - Stanford

Illinois

  • Northwestern University - Chicago
  • Loyola University - Maywood
  • Advocate Christ Medical Center (Cardiac Surgery Clinical Research Center) - Oak Lawn

Maryland

  • University of Maryland Medical Center - Baltimore
  • The Johns Hopkins Hospital - Baltimore

Massachusetts

  • Tufts Medical Center - Boston
  • Massachusetts General Hospital - Boston

Arkansas

  • Saint Vincent Heart Clinic Arkansas - Little Rock

Colorado

  • University of Colorado - Aurora

Indiana

  • Saint Vincent Medical Group - Indianapolis

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2018-10-31
Est. Completion 2026-04

What the registry record for NCT03681210 still lists

NCT03681210 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 397-participant average among 12 other Chronic Heart Failure trials with a reported enrollment target (24% lower).

The record links to 1 condition, with Chronic Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which HeartWare Ventricular Assist Device is the first listed.

NCT03681210 names 20 study sites across 11 states, led by Florida, California, Illinois.

Frequently Asked Questions

What is clinical trial NCT03681210 about?

NCT03681210 is a clinical study titled "Destination Therapy Post Approval Study". Medtronic is sponsoring the HeartWare™ HVAD™ Destination Therapy (DT) Post Approval Study (PAS) to further confirm safety and effectiveness of the HeartWare Ventricular Assist Device System (HVAD System) when used as intended, in "real-world" clinical practice. The Destination Therapy Post Approval...

What is the current status of trial NCT03681210?

This trial is currently active not recruiting. The enrollment target is 300 participants. The study started on 2018-10-31. Estimated completion is 2026-04.

What conditions does trial NCT03681210 study?

This clinical trial studies the following conditions: Chronic Heart Failure.

What interventions are being tested in trial NCT03681210?

The interventions under investigation include: HeartWare Ventricular Assist Device (DEVICE).

Who is sponsoring clinical trial NCT03681210?

This trial is sponsored by Medtronic Cardiac Rhythm and Heart Failure, which has 115 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03681210 being conducted?

This trial has 20 study locations across Arkansas, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03681210's enrollment target sits among peer trials

300 4th of 12 higher than 9 of 12 other Chronic Heart Failure trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00353483 · 300 participants

    Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

  • NCT00588185 · 300 participants · NA

    [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • NCT00682032 · 300 participants · NA

    The Effect of Beta-glucan in Non-Small Cell Lung Cancer

  • NCT00870064 · 300 participants · NA

    The Treatment of Type I Open Fractures in Pediatrics

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03681210, the US trial registry maintained by the National Library of Medicine. NCT03681210 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.